2026-11-18


    Access to CAR-T cell therapy in China is set to improve significantly following a major reduction in treatment costs, creating new opportunities for patients both in China and around the world.


    On November 14, 2026, China's National Healthcare Security Administration announced the 2026 National Reimbursement Drug List, which includes Carteyva® (relmacabtagene autoleucel, relma-cel), a CD19-targeted CAR-T therapy developed by JW Therapeutics. It is the first and currently the only CAR-T therapy included in China's National Reimbursement Drug List. The updated list will take effect on January 1, 2027.


    Following its inclusion in the national reimbursement list, the medication cost is expected to decrease to approximately RMB 300,000, significantly lowering the financial barrier for eligible patients. According to information provided by the manufacturer, the adjusted price will apply to infusions administered on or after January 1, 2027, and is also available to international patients.


    Carteyva® is an autologous anti-CD19 CAR-T therapy approved by China's National Medical Products Administration (NMPA) for three indications in adult patients: relapsed or refractory large B-cell lymphoma (r/r LBCL), relapsed or refractory follicular lymphoma (r/r FL), and relapsed or refractory mantle cell lymphoma (r/r MCL).


    At Jiahui International Hospital, the Jiahui International Cell Therapy Center brings together experienced hematology and oncology specialists to support patients exploring advanced cell therapy options. The team provides professional assessments, treatment consultations, and medical support for both domestic and international patients.


    Jiahui International Cancer Center (JICC) has provided CAR-T treatment to patients from Singapore, Hong Kong SAR, Russia, Hungary, New Zealand, India, Pakistan, and other countries and regions. Building on its experience in treating international patients with advanced CAR-T therapies, JICC continues to expand access to innovative cell therapies for patients worldwide.


    Patients and families interested in CAR-T therapy are welcome to contact Jiahui Health to arrange a consultation with our hematology team, learn more about available treatment options, and explore whether CAR-T therapy may be suitable for them.


    Contact Jiahui International Cancer Center
    Email: internationaloffice@jiahui.com
    WhatsApp: +852 4619 1904
    WeChat: Jiahui-GSN

    Search

    Related news

    CONTACT US

    Follow us

    Jiahui's Partners

    Copyright © 2017 by Jiahui,Inc. All rights reserved 沪ICP备15019023号-1 | 沪公网安备 31010402004841 号

    2021-06-01
    • Scan the QR code to follow
      Expat account Jiahui Health